A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease
Clinical trial NCT02295501 · TERMINATED
Trial details
- NCT number
- NCT02295501
- Sponsor
- Cerus Corporation
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-12-01
- Primary completion
- 2020-12-01
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.